CHANGES IN ULTRASTRUCTURE OF HEPATOCYTES AND LIVER TEST-RESULTS BEFORE, DURING, AND AFTER TREATMENT WITH INTERFERON-BETA IN PATIENTS WITH HBEAG-POSITIVE CHRONIC ACTIVE HEPATITIS

被引:6
|
作者
ITOH, S
MARUTANI, K
MATSUO, S
机构
[1] Third Department of Medicine, Saitama Medical School, Saitama
关键词
HEPATITIS-B E-ANTIGEN-POSITIVE CHRONIC ACTIVE HEPATITIS; INTERFERON-BETA; ENDOPLASMIC RETICULUM; GLYCOGEN PARTICLES; ALANINE AMINOTRANSFERASE; ALBUMIN;
D O I
10.1007/BF01296570
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We studied the histological and ultrastructural changes in the liver and alterations in the fiver test results before, during, and after treatment with human interferon-beta from five patients with hepatitis B e antigen-positive chronic active hepatitis. A daily dose of 3 X 10(6) to 6 X 10(6) units of interferon-beta was given intravenously for four weeks. The total index of periportal and portal inflammation, intralobular degeneration, and focal necrosis before treatment was decreased significantly six months after treatment (P < 0.05). Ultrastructurally, the structure of endoplasmic reticulum was irregularly shaped or fragmentally decreased during treatment, but these disappeared six or 12 months after treatment. Glycogen particles diminished greatly during treatment. The alanine aminotransferase concentrations in these patients increased during treatment. Serum albumin and cholinesterase levels decreased significantly al the fourth week of treatment (P < 0.01) and at the third day (P < 0.01) to the second week (P < 0.05) of treatment, respectively. These results suggest that interferon-beta injures endoplasmic reticulum and glycogen areas and damages the cholinesterase activity in the early stage of treatment and protein synthesis in patients with hepatitis B e antigen-positive chronic active hepatitis.
引用
收藏
页码:1260 / 1267
页数:8
相关论文
共 50 条
  • [1] INTERFERON THERAPY IN PATIENTS WITH HBEAG-POSITIVE CHRONIC ACTIVE HEPATITIS
    OGAWA, Y
    HORIIKE, N
    ONJI, M
    MICHITAKA, K
    OHTA, Y
    JOURNAL OF MEDICAL VIROLOGY, 1987, 21 (04) : A121 - A121
  • [2] Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy
    Geng, Yan
    Wang, Xiangling
    Lu, Xiaolan
    Wu, Xiaokang
    Xu, Nan
    Han, Lei
    Xu, Jiru
    MEDICINE, 2016, 95 (05)
  • [3] Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α
    Yao-ren Hu
    Hua-dong Yan
    Guo-sheng Gao
    Cheng-liang Zhu
    Ji-fang Cheng
    Infection International(Electronic Edition), 2014, 3 (01) : 10 - 15
  • [4] TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS WITH HUMAN-LYMPHOBLASTOID INTERFERON - PRELIMINARY-RESULTS OF A CONTROLLED TRIAL
    SARACCO, G
    ROSINA, F
    RIZZETTO, M
    HEPATOLOGY, 1986, 6 (04) : 795 - 795
  • [5] Evaluation of efficiency of sequential therapy with interferon and lamivudine from changes of HBV cccDNA in liver in HBeAG-positive chronic hepatitis B patients
    Zhuang, L. W.
    Lu, H. Y.
    Si, C. W.
    Chen, X. Y.
    Chen, Y.
    Han, Z. H.
    Xu, J. H.
    Li, J.
    Yu, Y. Y.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S200 - S200
  • [6] Association of serum total cholesterol with pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients
    Xun, Zhen
    Lin, Jin-Piao
    Liu, Can
    Huang, Jin-Lan
    Shen, Ye
    Xu, Si-Yi
    Wu, Wen-Nan
    Ou, Qi-Shui
    ANTIVIRAL THERAPY, 2019, 24 (02) : 85 - 93
  • [7] Addition of (pegylated) interferon to entecavir increases response in treatment naive HBeAg-positive patients with chronic hepatitis B
    Liem, S.
    van Campenhout, M. J.
    Chi, H.
    Brouwer, W. P.
    Xie, Q.
    Qi, X.
    Liang, C.
    Tabak, F.
    Hansen, B. E.
    Janssen, H. L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S692 - S692
  • [8] Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B
    Pfefferkorn, Maria
    Schott, Tina
    Boehm, Stephan
    Deichsel, Danilo
    Felkel, Christin
    Gerlich, Wolfram H.
    Glebe, Dieter
    Wat, Cynthia
    Pavlovic, Vedran
    Heyne, Renate
    Berg, Thomas
    van Boemmel, Florian
    JOURNAL OF HEPATOLOGY, 2021, 74 (02) : 283 - 292
  • [9] Serum hepatitis B core-related antigen as a treatment predictor during pegylated interferon therapy in patients with HBeAg-positive chronic hepatitis B
    Chuaypen, Natthaya
    Posuwan, Nawarat
    Payungporn, Sunchai
    Tanaka, Yasuhito
    Poovorawan, Yong
    Tangkijvanich, Pisit
    HEPATOLOGY, 2015, 62 : 1214A - 1214A
  • [10] Predictors of HBeAg loss in HBeAg-positive patients with chronic hepatitis B during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate
    Pan, Calvin Q.
    Li, Michael Kin Kong
    Lee, Kwan Sik
    Balabanska, Rozalina I.
    Flaherty, John F.
    Kim, Kyungpil
    Myers, Robert P.
    Subramanian, Mani
    Abdurakhmanov, Djamal
    Ma, Mang M.
    Bae, Ho
    Agarwal, Kosh
    HEPATOLOGY, 2016, 64 : 931A - 931A